Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration

Authors: Katharine L Sodek, Theodore J Brown, Maurice J Ringuette

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

The invasive potential of cancer cells is usually assessed in vitro using Matrigel as a surrogate basement membrane. Yet cancer cell interaction with collagen I matrices is critical, particularly for the peritoneal metastatic route undertaken by several cancer types including ovarian. Matrix metalloprotease (MMP) activity is important to enable cells to overcome the barrier constraints imposed by basement membranes and stromal matrices in vivo. Our objective was to compare matrices reconstituted from collagen I and Matrigel as representative barriers for ovarian cancer cell invasion.

Methods

The requirement of MMP activity for ovarian cancer cell penetration of Matrigel and collagen matrices was assessed in 2D transwell and 3D spheroid culture systems.

Results

The broad range MMP inhibitor GM6001 completely prevented cell perforation of polymerised collagen I-coated transwell membranes. In contrast, GM6001 decreased ES-2 cell penetration of Matrigel by only ~30% and had no effect on HEY cell Matrigel penetration. In 3D culture, ovarian cancer cells grown as spheroids also migrated into surrounding Matrigel matrices despite MMP blockade. In contrast, MMP activity was required for invasion into 3D matrices of collagen I reconstituted from acid-soluble rat-tail collagen I, but not from pepsin-extracted collagen I (Vitrogen/Purecol), which lacks telopeptide regions.

Conclusion

Matrigel does not form representative barriers to ovarian cancer cells in either 2D or 3D culture systems. Our findings support the use of collagen I rather than Matrigel as a matrix barrier for invasion studies to better approximate critical interactions and events associated with peritoneal metastasis.
Appendix
Available only for authorised users
Literature
1.
Munshi HG, Stack MS: Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev. 2006, 25 (1): 45-56. 10.1007/s10555-006-7888-7.CrossRefPubMed
2.
Brinckerhoff CE, Rutter JL, Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000, 6 (12): 4823-4830.PubMed
3.
Ellerbroek SM, Stack MS: Membrane associated matrix metalloproteinases in metastasis. BioEssays. 1999, 21 (11): 940-949. 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.0.CO;2-J.CrossRefPubMed
4.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000, 18 (5): 1135-1149.PubMed
5.
Albini A, Benelli R, Noonan DM, Brigati C: The "chemoinvasion assay": a tool to study tumor and endothelial cell invasion of basement membranes. Int J Dev Biol. 2004, 48 (5-6): 563-571. 10.1387/ijdb.041822aa.CrossRefPubMed
6.
Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ: A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev. 2006, 20 (19): 2673-2686. 10.1101/gad.1451806.CrossRefPubMedPubMedCentral
7.
Kleinman HK, Martin GR: Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005, 15 (5): 378-386. 10.1016/j.semcancer.2005.05.004.CrossRefPubMed
8.
Bartolome RA, Galvez BG, Longo N, Baleux F, Van Muijen GN, Sanchez-Mateos P, Arroyo AG, Teixido J: Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res. 2004, 64 (7): 2534-2543. 10.1158/0008-5472.CAN-03-3398.CrossRefPubMed
9.
Albini A: Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res. 1998, 4 (3): 230-241.CrossRefPubMed
10.
Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47 (12): 3239-3245.PubMed
11.
Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM, Flavia Di Renzo M: The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res. 2003, 288 (2): 382-389. 10.1016/S0014-4827(03)00250-7.CrossRefPubMed
12.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66.CrossRefPubMed
13.
Freedman RS, Deavers M, Liu J, Wang E: Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med. 2004, 2 (1): 23-10.1186/1479-5876-2-23.CrossRefPubMedPubMedCentral
14.
Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM: Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res. 2005, 11 (1): 113-122. 10.1158/1078-0432.CCR-04-2548.PubMed
15.
Stratton JF, Tidy JA, Paterson ME: The surgical management of ovarian cancer. Cancer Treat Rev. 2001, 27 (2): 111-118. 10.1053/ctrv.2000.0196.CrossRefPubMed
16.
Jatoi A, Podratz KC, Gill P, Hartmann LC: Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. J Support Oncol. 2004, 2 (4): 323-337.PubMed
17.
Ghosh S, Wu Y, Stack MS: Ovarian cancer-associated proteinases. Cancer Treatment and Research. 2002, 107: 331-351.PubMed
18.
Melichar B, Freedman RS: Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer. 2002, 12 (1): 3-17. 10.1046/j.1525-1438.2002.01093.x.CrossRefPubMed
19.
Kenny HA, Krausz T, Yamada SD, Lengyel E: Use of a novel 3D culture model to elucidate the role of mesothelial cells,fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007, 121 (7): 1463-10.1002/ijc.22874.CrossRefPubMed
20.
Mochizuki Y, Nakanishi H, Kodera Y, Ito S, Yamamura Y, Kato T, Hibi K, Akiyama S, Nakao A, Tatematsu M: TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clinical & Experimental Metastasis. 2004, 21 (1): 39-47. 10.1023/B:CLIN.0000017181.01474.35.CrossRef
21.
Witz CA, Montoya-Rodriguez IA, Cho S, Centonze VE, Bonewald LF, Schenken RS: Composition of the extracellular matrix of the peritoneum. J Soc Gynecol Investig. 2001, 8 (5): 299-304. 10.1016/S1071-5576(01)00122-8.CrossRefPubMed
22.
Kawamura T, Endo Y, Yonemura Y, Nojima N, Fujita H, Fujimura T, Obata T, Yamaguchi T, Sasaki T: Significance of integrin alpha2/beta1 in peritoneal dissemination of a human gastric cancer xenograft model. Int J Oncol. 2001, 18 (4): 809-815.PubMed
23.
Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M: Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer. 1996, 74 (9): 1406-1412.CrossRefPubMedPubMedCentral
24.
Ellerbroek SM, Wu YI, Overall CM, Stack MS: Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. Journal of Biological Chemistry. 2001, 276 (27): 24833-24842. 10.1074/jbc.M005631200.CrossRefPubMed
25.
Fishman DA, Kearns A, Chilukuri K, Bafetti LM, O'Toole EA, Georgacopoulos J, Ravosa MJ, Stack MS: Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis. 1998, 18 (1): 15-26. 10.1159/000024495.CrossRefPubMed
26.
Skubitz AP: Adhesion molecules. Cancer Treat Res. 2002, 107: 305-329.PubMed
27.
Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N: Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007, 6: 11-10.1186/1477-3163-6-11.CrossRefPubMedPubMedCentral
28.
Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS: Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. International Journal of Cancer. 1996, 67 (5): 695-701. 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.0.CO;2-4.CrossRefPubMed
29.
Burleson KM, Hansen LK, Skubitz AP: Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis. 2004, 21 (8): 685-697. 10.1007/s10585-004-5768-5.CrossRefPubMed
30.
Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK: Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng. 2003, 83 (2): 173-180. 10.1002/bit.10655.CrossRefPubMed
31.
Sodek KL, Ringuette MJ, Brown TJ: MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer. 2007, 97 (3): 358-367. 10.1038/sj.bjc.6603863.CrossRefPubMedPubMedCentral
32.
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001, 114 (Pt 1): 111-118.PubMed
33.
Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, Hudson LG, Stack MS: Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 2007, 67 (5): 2030-2039. 10.1158/0008-5472.CAN-06-2808.CrossRefPubMed
34.
Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988, 240 (4849): 177-184. 10.1126/science.2451290.CrossRefPubMed
35.
Mueller-Klieser W: Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol. 1997, 273 (4 Pt 1): C1109-23.PubMed
36.
Helseth DL, Veis A: Collagen self-assembly in vitro. Differentiating specific telopeptide-dependent interactions using selective enzyme modification and the addition of free amino telopeptide. J Biol Chem. 1981, 256 (14): 7118-7128.PubMed
37.
Franzblau C, Kang AH, Faris B: In vitro formation of intermolecular crosslinks in chick skin collagen. II. Kinetics. Biochem Biophys Res Commun. 1970, 40 (2): 437-444. 10.1016/0006-291X(70)91028-4.CrossRefPubMed
38.
Hagiwara A, Takahashi T, Sawai K, Taniguchi H, Shimotsuma M, Okano S, Sakakura C, Tsujimoto H, Osaki K, Sasaki S: Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res. 1993, 53 (3): 687-692.PubMed
39.
Cui L, Johkura K, Liang Y, Teng R, Ogiwara N, Okouchi Y, Asanuma K, Sasaki K: Biodefense function of omental milky spots through cell adhesion molecules and leukocyte proliferation. Cell Tissue Res. 2002, 310 (3): 321-330. 10.1007/s00441-002-0636-6.CrossRefPubMed
40.
Krist LF, Kerremans M, Broekhuis-Fluitsma DM, Eestermans IL, Meyer S, Beelen RH: Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother. 1998, 47 (4): 205-212. 10.1007/s002620050522.CrossRefPubMed
41.
Zhang XY, Pettengell R, Nasiri N, Kalia V, Dalgleish AG, Barton DP: Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources. J Soc Gynecol Investig. 1999, 6 (6): 333-340. 10.1016/S1071-5576(99)00040-4.CrossRefPubMed
42.
Stadlmann S, Raffeiner R, Amberger A, Margreiter R, Zeimet AG, Abendstein B, Moser PL, Mikuz G, Klosterhalfen B, Offner FA: Disruption of the integrity of human peritoneal mesothelium by interleukin-1beta and tumor necrosis factor-alpha. Virchows Archiv. 2003, 443 (5): 678-685. 10.1007/s00428-003-0867-2.CrossRefPubMed
43.
Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003, 3 (6): 422-433. 10.1038/nrc1094.CrossRefPubMed
44.
Engbring JA, Kleinman HK: The basement membrane matrix in malignancy. J Pathol. 2003, 200 (4): 465-470. 10.1002/path.1396.CrossRefPubMed
45.
Matsuoka T, Yashiro M, Nishimura S, Inoue T, Fujihara T, Sawada T, Kato Y, Seki S, Hirakawa-Ys Chung K: Increased expression of alpha2beta1-integrin in the peritoneal dissemination of human gastric carcinoma. Int J Mol Med. 2000, 5 (1): 21-25.PubMed
46.
Takatsuki H, Komatsu S, Sano R, Takada Y, Tsuji T: Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). Cancer Res. 2004 , 64 (17): 6065-6070. 10.1158/0008-5472.CAN-04-0321.CrossRefPubMed
47.
Prockop DJ, Fertala A: Inhibition of the self-assembly of collagen I into fibrils with synthetic peptides. Demonstration that assembly is driven by specific binding sites on the monomers. J Biol Chem. 1998, 273 (25): 15598-15604. 10.1074/jbc.273.25.15598.CrossRefPubMed
48.
Noel AC, Calle A, Emonard HP, Nusgens BV, Simar L, Foidart J, Lapiere CM, Foidart JM: Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype.[see comment]. Cancer Res. 1991, 51 (1): 405-414.PubMed
49.
Simon N, Noel A, Foidart JM: Evaluation of in vitro reconstituted basement membrane assay to assess the invasiveness of tumor cells. Invasion Metastasis. 1992, 12 (3-4): 156-167.PubMed
50.
Mackinnon WB, Hancock R, Dyne M, Russell P, Mountford CE: Evaluation of an in vitro invasion assay for use on solid tissue samples and cultured cells. Invasion Metastasis. 1992, 12 (5-6): 241-252.PubMed
51.
Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer. 2002, 2 (3): 161-174. 10.1038/nrc745.CrossRefPubMed
52.
Sieuwerts AM, Klijn JG, Foekens JA: Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane. Clin Exp Metastasis. 1997, 15 (1): 53-62. 10.1023/A:1018436407280.CrossRefPubMed
53.
Cheung LW, Leung PC, Wong AS: Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res. 2006, 66 (22): 10902-10910. 10.1158/0008-5472.CAN-06-2217.CrossRefPubMed
54.
Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS: RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene. 2004, 23 (52): 8486-8496. 10.1038/sj.onc.1207879.CrossRefPubMed
55.
Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M: Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene. 2003, 22 (54): 8716-8722. 10.1038/sj.onc.1206962.CrossRefPubMed
56.
Kolkhorst V, Sturzebecher J, Wiederanders B: Inhibition of tumour cell invasion by protease inhibitors: correlation with the protease profile. J Cancer Res Clin Oncol. 1998, 124 (11): 598-606. 10.1007/s004320050221.CrossRefPubMed
57.
Rofstad EK, Mathiesen B, Kindem K, Galappathi K: Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006, 66 (13): 6699-6707. 10.1158/0008-5472.CAN-06-0983.CrossRefPubMed
58.
Nishikawa H, Ozaki Y, Nakanishi T, Blomgren K, Tada T, Arakawa A, Suzumori K: The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol. 2004, 92 (3): 881-886. 10.1016/j.ygyno.2003.11.017.CrossRefPubMed
59.
Sahai E, Marshall CJ: Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.[see comment]. Nat Cell Biol. 2003, 5 (8): 711-719. 10.1038/ncb1019.CrossRefPubMed
60.
Friedl P, Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003, 3 (5): 362-374. 10.1038/nrc1075.CrossRefPubMed
61.
Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, Friedl P: Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol. 2003, 160 (2): 267-277. 10.1083/jcb.200209006.CrossRefPubMedPubMedCentral
62.
Even-Ram S, Yamada KM: Cell migration in 3D matrix. Curr Opin Cell Biol. 2005, 17 (5): 524-532. 10.1016/j.ceb.2005.08.015.CrossRefPubMed
63.
Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, Lopez-Otin C, Shapiro S, Inada M, Krane S, Allen E, Chung D, Weiss SJ: Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol. 2004, 167 (4): 769-781. 10.1083/jcb.200408028.CrossRefPubMedPubMedCentral
64.
Terranova VP, Liotta LA, Russo RG, Martin GR: Role of laminin in the attachment and metastasis of murine tumor cells. Cancer Res. 1982, 42 (6): 2265-2269.PubMed
65.
Givant-Horwitz V, Davidson B, Reich R: Laminin-induced signaling in tumor cells. Cancer Lett. 2005, 223 (1): 1-10. 10.1016/j.canlet.2004.08.030.CrossRefPubMed
Metadata
Title
Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration
Authors
Katharine L Sodek
Theodore J Brown
Maurice J Ringuette
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-223

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma

Commentary

Ampullary adenocarcinoma – differentiation matters

Research article

Increase in mammography detected breast cancer over time at a community based regional cancer center: a longitudinal cohort study 1990–2005

Research article

Antioxidant intervention of smoking-induced lung tumor in mice by vitamin E and quercetin

Research article

FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

Research article

Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits